Categorynews

Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor – Global Pipeline Insight Report 2019 – ResearchAndMarkets.com

November 6, 2019 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products

The report assesses the active Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report

  • Provides a snapshot of the therapeutics pipeline activity for Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor
  • Features the Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages
  • Offers detailed therapeutic product profiles of Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor

Reasons to Buy

  • Establish a comprehensive understanding of the current pipeline scenario across Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor research & development (R&D)
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify and understand the sought after therapy areas and indications for Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor
  • Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor to enhance and expand business potential and scope
  • Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress

Companies Mentioned

  • Boehringer Ingelheim
  • Wyeth
  • Sihuan Pharmaceutical Holdings Group
  • XuanZhu Pharma
  • BDL Products Inc.
  • CARgenix Holdings LLC
  • Sorrento Therapeutics

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/cd671z

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900